bUrRpPPP!, I notice that in Taylor Cox’s, Benzinga article AVXL is not mentioned.
Dr. Alkon of Neurotrope states:
"There is a long line of trials, all going after amyloid in different ways that never have worked. What we're trying to say is, look at the elephant in the room. The elephant in the room is look at the loss of wiring in the brain."
My question is does AVXL fall into the treating amyloid deposits hypothesis camp or not?
If it does, according to Dr.Alkon, the implications are not good.
Market Data 
Markets 
AI
